Quantcast

Elsevier Announces the Launch of New Open Access Journal, Schizophrenia Research: Cognition

March 27, 2014

NEW YORK, March 27, 2014 /PRNewswire/ –

Elsevier [http://www.elsevier.com ], a world-leading provider of scientific, technical
and medical information products and services, today announced the launch of Schizophrenia
Research: Cognition [http://www.schizrescognition.com ], a new open access journal
dedicated to publishing original research, concise research reports, brief reports,
letters to the editor, and review papers addressing the role of cognitive functioning in
schizophrenia.

As a spin-off from companion journal Schizophrenia Research, which is one of the most
recognized journals in the field, Schizophrenia Research: Cognition specializes in
providing a forum on all aspects of cognition in schizophrenia, including clinical
neuropsychology, neurocognition, social cognition, functional capacity, cognitive and
social neuroscience, and aspects of everyday outcome as related to cognition. Articles
that compare the influence of cognition and other influences on outcome in schizophrenia
will also be published as will research on descriptive characteristics, genetic
influences, pharmacological and non-pharmacological treatments, and neuroimaging
correlates of these aspects of cognition.

Schizophrenia Research: Cognition is an online-only journal and articles will be
published rapidly after acceptance. The journal will publish the latest developments in
the field, which currently are too often scattered among a host of other journals that do
not always prominently feature these articles. Schizophrenia Research: Cognition will
bring together research from other scientific disciplines including, neuroscience,
genomics, and psychiatry.

Dr. Philip D. Harvey, Editor-in-Chief of Schizophrenia Research: Cognition, explained,
“The benefits of an international, specialized open-access journal focusing on cognition
in schizophrenia will include broadening access to the rapidly changing developments in
the field to scientists with limited access to subscription journals.”

Published articles are now available on ScienceDirect
[http://www.sciencedirect.com/science/journal/aip/22150013 ] and

http://www.SchizResCognition.com

For more information or to submit an article, go to:

http://www.SchizResCognition.com or

http://www.elsevier.com/journals/schizophrenia-research-cognition/2215-0013

# # #

About Elsevier

Elsevier is a world-leading provider of information solutions that enhance the
performance of science, health, and technology professionals, empowering them to make
better decisions, deliver better care, and sometimes make groundbreaking discoveries that
advance the boundaries of knowledge and human progress. Elsevier provides web-based,
digital solutions – among them ScienceDirect [http://www.sciencedirect.com ], Scopus
[http://www.scopus.com ], Elsevier Research Intelligence
[http://www.elsevier.com/online-tools/research-intelligence ] and ClinicalKey
[https://www.clinicalkey.com ] – and publishes nearly 2,200 journals, including The Lancet
[http://www.thelancet.com ] and Cell [http://www.cell.com ], and over 25,000 book titles,
including a number of iconic reference works.

The company is part of Reed Elsevier Group PLC [http://www.reedelsevier.com ], a
world-leading provider of professional information solutions in the Science, Medical,
Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed
Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange),
RUK and ENL (New York Stock Exchange).

        Media contact
        Natalie Hill-krasniqi
        Elsevier
        +44(0)20-7424-4404
        n.hill-krasniqi@elsevier.com

SOURCE Elsevier


Source: PR Newswire



comments powered by Disqus